Cartesian Therapeutics Stock Probability of Future Stock Price Finishing Over 7.28
| RNAC Stock | 7.28 0.12 1.62% |
Closest to current price Cartesian long PUT Option Payoff at Expiration
Cartesian | Build AI portfolio with Cartesian Stock |
Cartesian Therapeutics Target Price Odds to finish over 7.28
The tendency of Cartesian Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.28 | 90 days | 7.28 | about 65.66 |
Based on a normal probability distribution, the odds of Cartesian Therapeutics to move above the current price in 90 days from now is about 65.66 (This Cartesian Therapeutics probability density function shows the probability of Cartesian Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Cartesian Therapeutics has a beta of 0.29 indicating as returns on the market go up, Cartesian Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cartesian Therapeutics will be expected to be much smaller as well. Additionally Cartesian Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Cartesian Therapeutics Price Density |
| Price |
Predictive Modules for Cartesian Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cartesian Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cartesian Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cartesian Therapeutics is not an exception. The market had few large corrections towards the Cartesian Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cartesian Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cartesian Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.24 | |
β | Beta against Dow Jones | 0.29 | |
σ | Overall volatility | 0.62 | |
Ir | Information ratio | -0.06 |
Cartesian Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cartesian Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cartesian Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cartesian Therapeutics generated a negative expected return over the last 90 days | |
| Cartesian Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 38.91 M. Net Loss for the year was (77.42 M) with loss before overhead, payroll, taxes, and interest of (51.76 M). | |
| Cartesian Therapeutics currently holds about 106.44 M in cash with (23.67 M) of positive cash flow from operations. | |
| Roughly 61.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from globenewswire.com: Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinsons Disease |
Cartesian Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cartesian Stock often depends not only on the future outlook of the current and potential Cartesian Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cartesian Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 23.7 M | |
| Cash And Short Term Investments | 212.6 M |
Cartesian Therapeutics Technical Analysis
Cartesian Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Cartesian Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cartesian Therapeutics. In general, you should focus on analyzing Cartesian Stock price patterns and their correlations with different microeconomic environments and drivers.
Cartesian Therapeutics Predictive Forecast Models
Cartesian Therapeutics' time-series forecasting models is one of many Cartesian Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cartesian Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Cartesian Therapeutics
Checking the ongoing alerts about Cartesian Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cartesian Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cartesian Therapeutics generated a negative expected return over the last 90 days | |
| Cartesian Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 38.91 M. Net Loss for the year was (77.42 M) with loss before overhead, payroll, taxes, and interest of (51.76 M). | |
| Cartesian Therapeutics currently holds about 106.44 M in cash with (23.67 M) of positive cash flow from operations. | |
| Roughly 61.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from globenewswire.com: Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinsons Disease |
Check out Cartesian Therapeutics Backtesting, Cartesian Therapeutics Valuation, Cartesian Therapeutics Correlation, Cartesian Therapeutics Hype Analysis, Cartesian Therapeutics Volatility, Cartesian Therapeutics History as well as Cartesian Therapeutics Performance. For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Will Biotechnology sector continue expanding? Could Cartesian diversify its offerings? Factors like these will boost the valuation of Cartesian Therapeutics. Anticipated expansion of Cartesian directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cartesian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.07) | Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth 0.168 | Return On Assets |
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Cartesian Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cartesian Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cartesian Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.